{"id":15055,"date":"2016-01-07T15:43:57","date_gmt":"2016-01-07T15:43:57","guid":{"rendered":"https:\/\/ipo.org\/?p=15055"},"modified":"2016-01-14T20:10:46","modified_gmt":"2016-01-14T20:10:46","slug":"double-patenting-impact-of-gilead-on-bio-and-pharma","status":"publish","type":"post","link":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/","title":{"rendered":"Double-Patenting: Impact of Gilead on Bio and Pharma"},"content":{"rendered":"<p>The Federal Circuit decision twenty months ago in <em>Gilead v. Natco<\/em> arose out of ANDA litigation over patents on anti-viral drugs, and it is widely seen as expanding the universe of patents vulnerable to charges of double patenting in the pharma and biotech industry. However, life sciences companies are not the only ones to find themselves with Gilead\u2019s problem. After asserting a patent in litigation, some high-tech companies have discovered that the defendant can use one of the plaintiff\u2019s later issued, but earlier expiring patents, to knock out a patent that was issued earlier but expires later.<\/p>\n<p>Like drugmakers, some tech companies may come to regret relying heavily on continuations in their patent prosecution, using a \u201cmore is more\u201d strategy to grow large patent families. Ex parte reexamination has emerged as the proceeding of choice for tech patent challengers, with at least a dozen patents invalidated by the USPTO\u2019s Central Reexamination Unit for double patenting since <em>Gilead<\/em>.<\/p>\n<p>This panel will focus on tips for patent prosecution after <em>Gilead<\/em>, as well as the litigation outlook with a particular focus on biosimilars. Because many branded pharma companies are entering the biosimilar market, they are finding themselves combing the portfolios of competitors for double patenting weakness, much as generic companies are doing. Our panel features the lawyer who argued for Natco at the Federal Circuit, a law firm biotech lawyer who is an expert on patent term adjustment, and the vice president of IP at a drug development company.<\/p>\n<p>&nbsp;<\/p>\n<p>Speakers:<\/p>\n<p style=\"padding-left: 30px;\">Tim Babcock,<em> Akros Pharma Inc.<\/em><br \/>\nJack Brennan, <em>Fish &amp; Richardson<\/em><br \/>\nJeremy Lowe, <em>Axinn Veltrop<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Federal Circuit decision twenty months ago in Gilead v.  [&#8230;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-15055","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Double-Patenting: Impact of Gilead on Bio and Pharma - Intellectual Property Owners Association<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Double-Patenting: Impact of Gilead on Bio and Pharma - Intellectual Property Owners Association\" \/>\n<meta property=\"og:description\" content=\"The Federal Circuit decision twenty months ago in Gilead v. [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Intellectual Property Owners Association\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IPOAssociation\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-01-07T15:43:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-01-14T20:10:46+00:00\" \/>\n<meta name=\"author\" content=\"ipoadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipo\" \/>\n<meta name=\"twitter:site\" content=\"@ipo\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ipoadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/double-patenting-impact-of-gilead-on-bio-and-pharma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/double-patenting-impact-of-gilead-on-bio-and-pharma\\\/\"},\"author\":{\"name\":\"ipoadmin\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/8226b50acbf234bbf0f5d70f4a84ba47\"},\"headline\":\"Double-Patenting: Impact of Gilead on Bio and Pharma\",\"datePublished\":\"2016-01-07T15:43:57+00:00\",\"dateModified\":\"2016-01-14T20:10:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/double-patenting-impact-of-gilead-on-bio-and-pharma\\\/\"},\"wordCount\":273,\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/double-patenting-impact-of-gilead-on-bio-and-pharma\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/double-patenting-impact-of-gilead-on-bio-and-pharma\\\/\",\"name\":\"Double-Patenting: Impact of Gilead on Bio and Pharma - Intellectual Property Owners Association\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\"},\"datePublished\":\"2016-01-07T15:43:57+00:00\",\"dateModified\":\"2016-01-14T20:10:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/double-patenting-impact-of-gilead-on-bio-and-pharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ipo.org\\\/index.php\\\/double-patenting-impact-of-gilead-on-bio-and-pharma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/double-patenting-impact-of-gilead-on-bio-and-pharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ipo.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Double-Patenting: Impact of Gilead on Bio and Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"name\":\"Intellectual Property Owners Association\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ipo.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\",\"name\":\"Intellectual Property Owners Association\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"contentUrl\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"width\":570,\"height\":226,\"caption\":\"Intellectual Property Owners Association\"},\"image\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/IPOAssociation\\\/\",\"https:\\\/\\\/x.com\\\/ipo\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ipoassociation\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/8226b50acbf234bbf0f5d70f4a84ba47\",\"name\":\"ipoadmin\",\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/author\\\/ipoadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Double-Patenting: Impact of Gilead on Bio and Pharma - Intellectual Property Owners Association","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Double-Patenting: Impact of Gilead on Bio and Pharma - Intellectual Property Owners Association","og_description":"The Federal Circuit decision twenty months ago in Gilead v. [...]","og_url":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/","og_site_name":"Intellectual Property Owners Association","article_publisher":"https:\/\/www.facebook.com\/IPOAssociation\/","article_published_time":"2016-01-07T15:43:57+00:00","article_modified_time":"2016-01-14T20:10:46+00:00","author":"ipoadmin","twitter_card":"summary_large_image","twitter_creator":"@ipo","twitter_site":"@ipo","twitter_misc":{"Written by":"ipoadmin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/#article","isPartOf":{"@id":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/"},"author":{"name":"ipoadmin","@id":"https:\/\/ipo.org\/#\/schema\/person\/8226b50acbf234bbf0f5d70f4a84ba47"},"headline":"Double-Patenting: Impact of Gilead on Bio and Pharma","datePublished":"2016-01-07T15:43:57+00:00","dateModified":"2016-01-14T20:10:46+00:00","mainEntityOfPage":{"@id":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/"},"wordCount":273,"publisher":{"@id":"https:\/\/ipo.org\/#organization"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/","url":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/","name":"Double-Patenting: Impact of Gilead on Bio and Pharma - Intellectual Property Owners Association","isPartOf":{"@id":"https:\/\/ipo.org\/#website"},"datePublished":"2016-01-07T15:43:57+00:00","dateModified":"2016-01-14T20:10:46+00:00","breadcrumb":{"@id":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ipo.org\/index.php\/double-patenting-impact-of-gilead-on-bio-and-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipo.org\/"},{"@type":"ListItem","position":2,"name":"Double-Patenting: Impact of Gilead on Bio and Pharma"}]},{"@type":"WebSite","@id":"https:\/\/ipo.org\/#website","url":"https:\/\/ipo.org\/","name":"Intellectual Property Owners Association","description":"","publisher":{"@id":"https:\/\/ipo.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipo.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ipo.org\/#organization","name":"Intellectual Property Owners Association","url":"https:\/\/ipo.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/","url":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","contentUrl":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","width":570,"height":226,"caption":"Intellectual Property Owners Association"},"image":{"@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IPOAssociation\/","https:\/\/x.com\/ipo","https:\/\/www.linkedin.com\/company\/ipoassociation\/"]},{"@type":"Person","@id":"https:\/\/ipo.org\/#\/schema\/person\/8226b50acbf234bbf0f5d70f4a84ba47","name":"ipoadmin","url":"https:\/\/ipo.org\/index.php\/author\/ipoadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/15055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/comments?post=15055"}],"version-history":[{"count":1,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/15055\/revisions"}],"predecessor-version":[{"id":15057,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/15055\/revisions\/15057"}],"wp:attachment":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/media?parent=15055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/categories?post=15055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/tags?post=15055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}